SLC5A2 and hydrops fetalis: Evidence from subgroup analyses, particularly the DAPA-HF trial, indicates that the benefits of dapagliflozin are preserved regardless of background sacubitril/valsartan therapy, suggesting that SGLT2 inhibitors retain their efficacy even when added to optimized ARNI-based regimens.